FMC beats low Q1 bar but cash conversion remains the controlling variable

What happened

FMC's Q1 2026 revenue fell 4% to $759 million and adjusted EBITDA dropped 40% to $72 million, yet both exceeded the high end of guidance—a modest beat against already depressed expectations. GAAP net loss widened to $281 million, or $2.25 per share, while adjusted loss per share was $0.23, deteriorating 41 cents year-over-year. The company reaffirmed its full-year 2026 outlook, which implies no material improvement in the trajectory: revenue ex-India down ~5%, adjusted EBITDA down ~17%, and free cash flow ranging from negative $65 million to positive $65 million at the midpoint. The Latin America collection delays and working capital drag that drove the 2025 cash squeeze persist, and the reaffirmed guidance offers no evidence of a near-term inflection. Despite the headline beat, the underlying credit-shaped equity remains dependent on cash conversion, not demand recovery, and the path to deleveraging remains unclear.

Implication

FMC's Q1 results modestly exceeded lowered guidance, but the reaffirmed full-year outlook confirms that the cash squeeze and working capital headwinds persist. The equity remains priced as a levered turnaround where returns hinge on Latin America collections normalizing and debt reduction, neither of which is demonstrated in this quarter. Without a clear inflection in operating cash flow and reduced reliance on receivables monetization, the risk-reward favors waiting for confirmation. The dividend cut and covenant constraints limit downside optionality, but any re-rating requires tangible deleveraging, not just earnings beats. Stay on the sidelines until Q2 results provide cleaner evidence of cash conversion.

Thesis delta

The Q1 beat is a tactical positive against low expectations but does not alter the core thesis: FMC is a credit-shaped equity where equity returns depend on near-term cash conversion, not demand. The reaffirmed full-year outlook suggests management sees no material acceleration in collections or cost improvement, reinforcing the need for patience. The stock remains a wait, as the risk of another covenant request or further working capital deterioration outweighs the marginal upside from a modest guidance beat.